There has been a resurgence of interest in cancer vaccines in recent years. One of the important new areas of research has been on personalized vaccines for cancer that seek to identify abnormal protein targets that are expressed only in the patient’s tumor cells, not in normal cells. This approach results in a more highly targeted vaccine that is likely to break tolerance toward the cancer cells. While promising, the current approaches are relatively inefficient and are likely to be expensive. Through its development efforts on VaxCelerate, VIC has gained access to a series of technologies that combined together may rapidly and inexpensively produce more targeted, immunogenic cancer vaccines. VIC is currently seed funding this project through a series of proof of concept studies.